Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 23, 2015 08:57 ET | Source: Arch Therapeutics, Inc.

Arch Therapeutics Announces Positive Safety Results for AC5 Surgical Hemostatic Device(TM) in Preclinical Toxicity Studies

WELLESLEY, MA--(Marketwired - Mar 23, 2015) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™ (AC5™) for use in...
February 23, 2015 08:57 ET | Source: Arch Therapeutics, Inc.

Pre-Clinical Animal Pilot Study Shows Arch Therapeutics' AC5(TM) Compared Favorably Versus a Popular Hemostatic Agent

WELLESLEY, MA--(Marketwired - Feb 23, 2015) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™ for use in bleeding during...
February 19, 2015 08:56 ET | Source: Arch Therapeutics, Inc.

Nanomedicine: Nanotechnology, Biology, and Medicine Publishes Preclinical Data on Arch Therapeutics' AC5 Surgical Hemostatic Device(TM)

WELLESLEY, MA--(Marketwired - Feb 19, 2015) - Positive data from an independent third-party research group study sponsored by Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"),...
February 17, 2015 08:00 ET | Source: Arch Therapeutics, Inc.

The British Standards Institution Classifies Arch Therapeutics' AC5(TM) as a Medical Device Within the European Union

WELLESLEY, MA--(Marketwired - Feb 17, 2015) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a medical device company and developer of the AC5 Surgical Hemostatic Device™...
January 13, 2015 08:57 ET | Source: Arch Therapeutics, Inc.

Arch Therapeutics Obtains Additional Positive Results for AC5 Surgical Hemostatic Device(TM) in Preclinical Safety Study

WELLESLEY, MA--(Marketwired - Jan 13, 2015) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™, obtained positive results when...
January 06, 2015 08:57 ET | Source: Arch Therapeutics, Inc.

Arch Therapeutics Announces Positive Results for AC5 Surgical Hemostatic Device(TM) in Biochemical and Cell Function Safety Studies

WELLESLEY, MA--(Marketwired - Jan 6, 2015) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™, obtained positive results...
December 17, 2014 08:57 ET | Source: Arch Therapeutics, Inc.

Arch Therapeutics to Present at The Biotech Showcase(TM) 2015 Conference on January 14th 2015

WELLESLEY, MA--(Marketwired - Dec 17, 2014) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™, announced that it would be...
November 24, 2014 16:00 ET | Source: Arch Therapeutics, Inc.

Arch Therapeutics to Present at LD Micro Main Event on December 4th 2014

WELLESLEY, MA--(Marketwired - Nov 24, 2014) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™, announced that it would be...
November 18, 2014 08:57 ET | Source: Arch Therapeutics, Inc.

Arch Therapeutics Reports Positive Preclinical Data from Study of AC5 Surgical Hemostatic Device(TM) in Animals Treated with Brilinta(R) (ticagrelor)

WELLESLEY, MA--(Marketwired - Nov 18, 2014) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostat Device™, announced that an independent...
November 10, 2014 08:57 ET | Source: Arch Therapeutics, Inc.

Arch Therapeutics Will Present at Two Investor Conferences in November

WELLESLEY, MA--(Marketwired - Nov 10, 2014) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™, announced that it would be...